Study Title: A Prospective Randomized Study of Ramucirumab (LY3009806;NSC749128) Plus Pembrolizumab (MK-3475;NSC776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent non-Small Cell Lung Cancer
For more information about the trial above please contact the study team: